Cargando…

Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention

BACKGROUND AND OBJECTIVE: Clopidogrel is frequently used as part of optimal dual antiplatelet therapy in high-bleeding risk patients with the acute coronary syndrome. The concentration of the inactive carboxylic acid metabolite of clopidogrel might be useful to evaluate the response to clopidogrel t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamiak-Giera, Urszula, Czerkawska, Anna, Olędzki, Szymon, Kurzawski, Mateusz, Safranow, Krzysztof, Jastrzębska, Maria, Gawrońska-Szklarz, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994215/ https://www.ncbi.nlm.nih.gov/pubmed/33270185 http://dx.doi.org/10.1007/s43440-020-00197-w

Ejemplares similares

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
por: Adamiak-Giera, Urszula, et al.
Publicado: (2021)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
por: Kiebist, Jan, et al.
Publicado: (2021)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Effect of ticagrelor and clopidogrel dual antiplatelet therapy on MPVLR, MAADP, and AA inhibition rate in acute coronary syndrome patients after percutaneous coronary intervention
por: Gao, Song-Tao, et al.
Publicado: (2023)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
por: Neubauer, Horst, et al.
Publicado: (2011)

Evaluation of the in vitro permeation parameters of topical ketoprofen and lidocaine hydrochloride from transdermal Pentravan(®) products through human skin
por: Adamiak-Giera, Urszula, et al.
Publicado: (2023)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Calcium channel blockers reduce the antiplatelet effect of clopidogrel
por: Siller-Matula, Jolanta M, et al.
Publicado: (2008)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
por: Hemlata,, et al.
Publicado: (2013)

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers
por: Seo, Kwon-Duk, et al.
Publicado: (2014)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
por: Amin, Arwa M., et al.
Publicado: (2017)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention
por: Dasgupta, Arijit, et al.
Publicado: (2009)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database
por: Noh, Yoojin, et al.
Publicado: (2016)

Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers
por: Lee, Wonjae, et al.
Publicado: (2010)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials
por: Li, Jingyuan, et al.
Publicado: (2023)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

Postoperative Bleeding Risk for Oral Surgery under Continued Clopidogrel Antiplatelet Therapy
por: Gröbe, Alexander, et al.
Publicado: (2015)

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel
por: Cirillo, Plinio, et al.
Publicado: (2020)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
por: Kang, Hyun Goo, et al.
Publicado: (2021)

Analysis of Gastrointestinal Prophylaxis in Patients Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel
por: Morneau, Kathleen M., et al.
Publicado: (2014)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Simultaneous determination of clopidogrel, 2-oxo-clopidogrel, and the thiol metabolite of clopidogrel in human plasma by LC-MS/MS
por: Xu, Lei, et al.
Publicado: (2022)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation
por: Marcano, Ana Lucrecia, et al.
Publicado: (2022)

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
por: Zhang, Yan-Jiao, et al.
Publicado: (2022)

The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention
por: Haji Aghajani, Mohammad, et al.
Publicado: (2018)

Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention
por: Jeong, Young-Hoon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lagt9imogjnr8btdtc30ulbi5r